SCHEMBL16379190

SCHEMBL16379190

CC(C)NC(=O)c1nn(-c2ccc(OCC[18F])cc2)c(=O)c2c(N)scc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.57
▸ ADORA1 P30542 10/20 0.57
▸ IDO1 P14902 1/20 0.56
▸ APP P05067 6/20 0.55
▸ KDM4E B2RXH2 5/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ ALOX15 P16050 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ CASP6 P55212 1/20 0.55
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ ALOX12 P18054 4/20 0.53
▸ CASP1 P29466 4/20 0.52
▸ HPGD P15428 2/20 0.51
▸ RECQL P46063 2/20 0.51
▸ APAF1 O14727 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15047111 1.00 MAPT (0.57) MAPTADORA1IDO1APPKDM4E
SCHEMBL15047013 0.95 MAPT (0.56) MAPTADORA1IDO1APPKDM4E
SCHEMBL16379194 0.95 MAPT (0.56) MAPTADORA1IDO1APPKDM4E
SCHEMBL15047113 0.92 MAPT (0.58) MAPTADORA1IDO1APPKDM4E
SCHEMBL16379173 0.90 MAPT (0.45) MAPTADORA1IDO1APPKDM4E
SCHEMBL16379141 0.90 MAPT (0.45) MAPTADORA1IDO1APPKDM4E
SCHEMBL15047025 0.89 MAPT (0.55) MAPTADORA1IDO1APPKDM4E
SCHEMBL16379220 0.89 MAPT (0.55) MAPTADORA1IDO1APPKDM4E
SCHEMBL15047066 0.87 MAPT (0.76) MAPTADORA1IDO1APPKDM4E
SCHEMBL20133311 0.86 MAPT (0.62) MAPTADORA1IDO1APPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150004100-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2015-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004100-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY MAPT, NAT1, APP MAPT 1/4885ADORA1 438/4885IDO1 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback